

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**COALITION FOR AFFORDABLE DRUGS  
VIII, LLC,**  
Petitioner,

v.

**THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,**  
Patent Owner.

**Case IPR2015-01836**  
Patent 7,932,268 B2

**PATENT OWNER'S CORRECTED MOTION TO AMEND UNDER 37  
C.F.R. § 42.121**

**TABLE OF CONTENTS**

	<u>Page</u>
I. INTRODUCTION .....	1
II. THE PROPOSED AMENDMENTS NARROW THE ISSUED CLAIMS ....	2
III. THE AMENDED CLAIMS ARE SUPPORTED BY THE WRITTEN DESCRIPTIONS .....	5
IV. THE AMENDED CLAIMS ARE PATENTABLE.....	10
A. Person of Ordinary Skill in the Art.....	10
B. The Amended Claims are Entitled to an Effective Filing Date of March 5, 2004 .....	10
C. The Substitute Claims are Patentable Over All Prior Art of Record.....	10
1. The amended claims are entitled to an invention date of no later than January 2004 .....	11
2. Pink Sheet and Stein post-date the invention date .....	13
3. The amended claims are patentable over other prior art of record.....	14
a) <i>Summary of References</i> .....	14
(i) Lomitapide Prior Art .....	14
(ii) Titration Art .....	16
b) <i>No reason to combine</i> .....	17
c) <i>No reasonable expectation of success</i> .....	20
d) <i>Objective indicia of nonobviousness confirm the patentability of the substitute claims</i> .....	22
(i) Unexpected Results. ....	22
(ii) Long-felt Need.....	22
(iii) Failure of Others.....	23
(iv) Praise .....	24
(v) Licensing/Commercial Success .....	24
4. Even if the Pink Sheet and Stein are prior art, the substitute claims are patentable .....	24
D. Patent Owner is Not Aware of Other Material Prior Art.....	25

V. CONCLUSION..... 25

**I. INTRODUCTION**

Inventor Dr. Daniel Rader designed and conducted the first clinical trial demonstrating that serious adverse side effects of lomitapide could be mitigated with forced titration, even at higher doses. He thus paved the way for clinical use of lomitapide as an adjunct therapy in patients suffering from HoFH, a severe genetic disease. Shortly after completing the clinical trial, Dr. Rader filed a provisional patent application describing his invention. Nevertheless, in its institution decision, the Board found that Petitioner had “reasonably shown” that Dr. Rader’s ’268 patent could not claim priority to that provisional application because the claimed “mg” dose ranges of the ’268 patent “are not obtained” from the “mg/kg” doses disclosed in the provisional and the claimed piperidine N-oxide derivative of the compound is not apparent from the provisional.

Although Patent Owner maintains its position that the ’268 patent claims are entitled to the March 5, 2004 priority date, in the event that the Board accepts the Petitioner’s obviousness arguments and deems the issued claims unpatentable, Patent Owner now contingently moves to substitute the canceled claim(s) with corresponding proposed amended claims 9-14. The amended claims clearly resolve both alleged deficiencies raised by Petitioner—first, by claiming dose ranges on a mg/kg basis; second, by eliminating the piperidine N-oxide derivative from the scope of the claim. *See* Appendix A.

The resulting substitute claims meet the requirements of 35 U.S.C. § 316(d)(3) insofar as they narrow the claims by, *inter alia*, shrinking the range of doses that may be administered in the claimed three-step method. In addition, the amended claims have express support in both the original disclosure of the '268 patent and the provisional application.

With priority thus established, two of the references relied upon to contend that the claimed method is obvious—Pink Sheet (Ex. 1013) and Stein (Ex. 1014)—do not qualify as prior art. Neither was published more than a year prior to the filing of Dr. Rader's patent application, and both were published *after* Dr. Rader conceived of and reduced to practice his invention. The third reference relied upon by Petitioner—Chang (Ex. 1015)—does not describe any dose regimen for lomitapide (let alone the claimed forced titration method) and is thus not anticipatory. Patent Owner is not aware of any art or teaching that a person of ordinary skill in the art (POSA) would combine with Chang (or any other material art) to render the proposed amended claims obvious. Accordingly, Patent Owner has met its burden of proving patentability of the proposed amended claims.

## **II. THE PROPOSED AMENDMENTS NARROW THE ISSUED CLAIMS**

The substitute claims retain the step-wise increasing dose regimen developed by Dr. Rader, but narrow the scope of the claims by: 1) narrowing the dose range and claiming it with reference to mg/kg/day dose amounts; and 2) claiming one

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.